NLTX
Closed
Neoleukin Therapeutics
3.49
-10.47 (-75.00%)
Last Update: 19 Dec 2023 17:30:00
Yesterday: 13.96
Day's Range: 3.49 - 3.49
Send
sign up or login to leave a comment!
When Written:
0.7
Neoleukin Therapeutics is a biopharmaceutical company that develops immunotherapies for cancer, autoimmune, and other diseases. The company is based in Seattle, Washington, and was founded in 2018.
Neoleukin Therapeutics uses a proprietary protein design technology called de novo protein design to create novel therapeutics that mimic the activity of natural cytokines, which are proteins that play a key role in the immune system. The company's lead product candidate, NL-201, is a de novo protein designed to activate the immune system against cancer.
Neoleukin Therapeutics has also developed a platform technology called IL-2 muteins, which are modified versions of the cytokine IL-2 that have improved therapeutic properties. The company has several IL-2 mutein product candidates in development for the treatment of autoimmune and inflammatory diseases.
Neoleukin Therapeutics has partnerships with several pharmaceutical companies, including Eli Lilly and Company, which has licensed the company's de novo protein design technology for the development of therapeutics for autoimmune and inflammatory diseases.
The company went public in July 2019 and is traded on the Nasdaq under the ticker symbol NLTX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Neoleukin Therapeutics uses a proprietary protein design technology called de novo protein design to create novel therapeutics that mimic the activity of natural cytokines, which are proteins that play a key role in the immune system. The company's lead product candidate, NL-201, is a de novo protein designed to activate the immune system against cancer.
Neoleukin Therapeutics has also developed a platform technology called IL-2 muteins, which are modified versions of the cytokine IL-2 that have improved therapeutic properties. The company has several IL-2 mutein product candidates in development for the treatment of autoimmune and inflammatory diseases.
Neoleukin Therapeutics has partnerships with several pharmaceutical companies, including Eli Lilly and Company, which has licensed the company's de novo protein design technology for the development of therapeutics for autoimmune and inflammatory diseases.
The company went public in July 2019 and is traded on the Nasdaq under the ticker symbol NLTX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!